An 18-year Follow-up Study on OSA in a Population-based Cohort

NCT05077748 | Completed

• 1 other identifier: FUOSA 3.1
• Study Type: observational
• Target: 202
• Locations: 1 country
• Sites: 1

Brief Summary

Our research team has established a polysomnography (PSG) quantified population-based paediatric sleep cohort in 2003 for a childhood OSA prevalence study. Subjects were recruited from 13 randomly selected primary schools. All subjects from this original cohort will be invited to join this 18-year follow-up study to repeat the following data collection: questionnaires, anthropometric measurement, sleep study, 24-hour ambulatory blood pressure (ABP) measurement, echocardiography and neurocognitive assessment.

Conditions

Epidemiology; Natural History; Obstructive Sleep Apnea; Cardiovascular Complication; Neurocognitive Dysfunction

Keywords

Obstructive sleep apnea; Sleep disordered breathing; Hypertension; Cardiovascular complication; Neurocognitive dysfunction

Outcome Measures

Primary Outcomes (1)

• OSA status at 18-year follow-up visit

  OSA status of the participants at the 18-year follow-up visit

  Through study completion, an average of 2 years

Secondary Outcomes (4)

• Factors associated with the persistence or the development of OSA in adulthood

  Through study completion, an average of 2 years

• Ambulatory blood pressure parameters at 18-year follow-up visit

  Through study completion, an average of 2 years

• Echocardiographic parameters at 18-year follow-up visit

  Through study completion, an average of 2 years

• Neurocognitive function at 18-year follow-up visit

  Through study completion, an average of 2 years

Eligibility Criteria

• Age: 18 Years - 35 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

In our current proposal, subjects from the 2003 cohort will be invited to join this follow-up study. Written consent will be obtained from the participants. The study protocol will be conducted in compliance with the Declaration of Helsinki. Ethics approval will be obtained from the Clinical Research Ethics Committee of the Joint Chinese University of Hong Kong - New Territories East Cluster.

You may qualify if:

• \- Subjects participants from the 2003 cohort

You may not qualify if:

• Neuromuscular disease
• Pathological central apnoea
• Severe chronic lung disease with documented hypoxaemia or awake oxygen saturation \<92%
• Chronic respiratory failure (unrelated to OSA)
• Acquired upper airway disease/obstruction
• Craniofacial abnormalities (e.g. secondary to trauma and malignancy)
• Other arrangement:
• Subjects who have any respiratory illness within 2 weeks of the scheduled follow-up visit will have their assessment re-arranged until they have fully recovered.
• Subjects taking medications that may affect sleep, upper airway patency or blood pressure (for example sedatives, stimulants, antihistamines, and cough medicine) within a week from recruitment will also be rescheduled to participate when they are free from medication use for at least 2 weeks.
• Subjects with hypertension and are on anti-hypertensive therapy are allowed to continue on their medication and the information will be obtained and recorded during data collection.

Sponsors & Collaborators

• Chinese University of Hong Kong: lead
• Food and Health Bureau, Hong Kong: collaborator

Study Sites (1)

Prince of Wales Hospital

Hong Kong, 999077, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Fasting blood samples will be taken from participants with venipuncture. The sample will be sent for biochemical measurements including lipid profile (Total cholesterol, total glycerides, high-density lipoprotein-cholesterol, low-density lipoprotein cholesterol) and serum glucose in the University Pathology Service. Plasma will also be collected in EDTA anticoagulant tubes, pre-processed and frozen at -80 degree Celsius for future analysis. Because of budget limitation, further blood test analysis is not included in the current proposal.

MeSH Terms

Conditions

Sleep Apnea, Obstructive; Cognition Disorders; Sleep Apnea Syndromes; Hypertension

Condition Hierarchy (Ancestors)

Apnea; Respiration Disorders; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Nervous System Diseases; Neurocognitive Disorders; Mental Disorders; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Ching Ching, Kate Dr. CHAN

  Chinese University of Hong Kong

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professional Consultant, Department of Paediatrics

Study Record Dates

• First Submitted: October 2, 2021
• First Posted: October 14, 2021
• Study Start: October 20, 2021
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: December 15, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)